A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461
Recruiting
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/30/2025
Locations: GastroIntestinal BioSciences, Los Angeles, California +196 locations
Conditions: Crohn's Disease
Register for Updates
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176
Recruiting
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Ironwood Cancer & Research Centers ( Site 0066), Chandler, Arizona +219 locations
Conditions: Breast Neoplasms
Register for Updates
BTX-A51 in Patients With Liposarcoma
NCT06414434
Recruiting
This study is testing if the recommended dose of BTX-A51 is safe and tolerable in participants with liposarcoma. The name of the study drug used in this research study is: -BTX-A51 (a type of kinase inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification
Register for Updates
Packed Red Blood Cell Transfusion During Cardiac Arrest
NCT06462027
Recruiting
The purpose of this pilot interventional study is to collect preliminary data on administering packed red blood cell (PRBC) during cardiac arrest (CA). The primary objective is to assess the feasibility of PRBC transfusion during cardiac CA to help optimize the methods required to augment cerebral and other vital organ oxygen delivery during cardiopulmonary resuscitation (CPR). The secondary objectives are to assess the effect of PRBC transfusion during prolonged cardiac arrests on cerebral oxyg... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/30/2025
Locations: NYU Langone Health, New York, New York
Conditions: Cardiac Arrest
Register for Updates
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs (OPTIMA)
NCT06532890
Recruiting
This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
04/30/2025
Locations: Columbia University, New York, New York +4 locations
Conditions: Cardiac Failure, Graft Rejection
Register for Updates
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT06596694
Recruiting
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: UCLA Hematology Oncology Santa Monica ( Site 1205), Santa Monica, California +50 locations
Conditions: Gastrointestinal Cancer
Register for Updates
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420
Recruiting
This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
04/30/2025
Locations: Medical Research of Arizona, Scottsdale, Arizona +29 locations
Conditions: Hereditary Angioedema
Register for Updates
A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms
NCT06693648
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 6-week trial of a formulation of AMZ001 once daily versus placebo once daily.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
04/30/2025
Locations: Millennium Clinical Trials, Thousand Oaks, California +10 locations
Conditions: Osteoarthritis of Knee, Osteoarthritis, Knee
Register for Updates
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, the PARRC Trial
NCT06770582
Recruiting
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of patients with non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, gemcitabine, 5-fluorouracil o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California +7 locations
Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Register for Updates
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
NCT06850038
Recruiting
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives. Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching. The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: NYU Langone - NYU Grossman School of Medicine, New York, New York +1 locations
Conditions: Alagille Syndrome
Register for Updates
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
NCT06906809
Recruiting
The purpose of this study is to investigate the effect of coadministration of phenytoin or itraconazole on the pharmacokinetics of BGB-16673 in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/30/2025
Locations: Fortrea Clinical Research Unit Inc, Madison, Wisconsin
Conditions: Healthy Volunteers
Register for Updates
Host Response to Infection and Treatment in Filarial Diseases
NCT00001230
Recruiting
This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment. Filarial infections are caused by parasitic worms. The immature worm (larva) is transmitted to a person through a mosquito bite and grows in the human body to 2 to 4 inches in length. Although many of these infections do not produce symptoms, especially in the early stages of infection, other... Read More
Gender:
ALL
Ages:
Between 3 years and 100 years
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis, Onchocerciasis
Register for Updates